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1. INTRODUCTION
Chemical warfare remains a serious threat despite
several international conventions and treaties signed to
prevent its use. The nitrogen mustards are closely related
chemically and toxicologically to the blister-inducing chemical
warfare agent sulphur mustard [1]. The nitrogen mustards,
viz., HN-1, HN-2, and HN-3 were synthesised during World
War I. HN-2, also known as mechlorethamine, was found
to be useful for the treatment of various types of malignancies
such as Hodgkin’s disease, lymphoma, and carcinoma of
solid tumors [2]. Few more nitrogen mustards are still
used as cytostatic agents, viz., melphalan, chlorambucil
and cyclophosphamide [3]. Nitrogen mustards and sulphur
mustard become biologically active after their intramolecular
cyclisation into immonium ions, aziridinium ions, or sulphonium
cations. All these mustards covalently bind to target
molecules via an alkylating reaction and produce a variety
of toxic effects [4]. DNA is probably the most important
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Nitrogen mustards (HN-1, HN-2 and HN-3) and sulphur mustard are alkylating and blister-inducing chemical
warfare agents. This study was aimed at investigating the prophylactic efficacy of amifostine, DRDE-07, and
their analogues and some recommended antidotes against dermally-applied nitrogen mustards and sulphur mustard
in preventing their systemic toxicity in mice. The antidotes were administered as single oral dose, 30 min prior
to the mustard agent application. For DRDE-07, 0.2 LD
50
 (249 mg/kg) was used and for other analogues, equimolar
dose of DRDE-07 was used. For amifostine, N-acetyl cysteine, melatonin and sodium thiosulphate, oral dose was
185 mg/kg, 250 mg/kg, 250 mg/kg, and 1000 mg/kg respectively. The animals were observed for mortality for
14 days. The protection index (PI) was calculated as a ratio of LD
50
 with treatment to LD
50
 without treatment.
The protection of the antidotes was also determined by intraperitoneal route and half of the oral dose of the
antidotes was given.  The estimated percutaneous LD
50
 of HN-1, HN-2, HN-3 and sulphur mustard was 11.9
mg/kg, 20.0 mg/kg, 7.1 mg/kg and 7.1 mg/kg, respectively.
Compounds that showed marginal protection against HN-1 were DRDE-10 and melatonin with a PI of 1.4.
Compounds that showed marginal protection against HN-2 were amifostine, DRDE-07, DRDE-09, DRDE-30,
DRDE-35 and melatonin with a PI of 1.4. Compounds that showed marginal protection against HN-3 were
amifostine, DRDE-30, DRDE-35, sodium thiosulphate and melatonin with a PI of 1.7. In the case of sulphur
mustard, DRDE-07, DRDE-10, DRDE-21, DRDE-30, and DRDE-35 gave a good protection with a PI of more
than 5.0. Amifostine and sodium thiosulphate gave a PI of 4.5 and 4.0, respectively, while DRDE-09, N-acetyl
cysteine and melatonin gave less protection against sulphur mustard. Intraperitoneally administered amifostine,
DRDE-30, sodium thiosulphate and melatonin gave marginal protection against HN-2 with a PI of 1.2,  while
intraperitoneally administered amifostine, DRDE-07, DRDE-09, DRDE-10, DRDE-30, DRDE-35 and melatonin
gave excellent protection against percutaneously administered sulphur mustard with a PI of more than 5.0. The
present study shows, that oral and intraperitoneal administration of amifostine, DRDE-07 and their analogues
are effective as prophylactic agents for sulphur mustard systemic toxicity, but not against nitrogen mustards.
Keywords: Nitrogen mustards, mechlorethamine, sulphur mustard, acute toxicity, amifostine, DRDE-07, prophylactic
efficacy, chemical warfare agents, antidotes
target of alkylation by nitrogen mustards.
At present, there are two main strategies to prevent
nitrogen mustards and sulphur mustard toxicity. First is
contact avoidance and the second is symptomatic treatment,
as there are no specific antidotes available to treat the
systemic toxicity. For the past two decades, a substantial
research effort for developing pharmacological intervention
strategies have been focused on in vitro studies aimed
at preventing or reversing the ability of sulphur mustard
to alkylate critical cell targets, disrupt calcium regulation,
cause cell death or cause other cell-mediated biochemical
disruptions [5,6]. Few compounds have shown good
prophylactic as well as therapeutic protection in vitro
[7,8] as well as in vivo against sulphur mustard [9-11].
Some drugs and chemicals have been reported to give
protection against sulphur and nitrogen mustards viz.,
N-acetyl cysteine, sodium thiosulphate, vitamin E [12-14]
Sodium thiosulphate has been recommended for the treatment
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of human poisoning by mustard gases [15,16]. Amifostine
and DRDE-07 [S-2 (2-aminoethylamino) ethyl phenyl sulphide]
have been shown to protect sulphur mustard toxicity as
a prophylactic agent [10,17,18]. This led researchers at
DRDE to study  amifostine, DRDE-07, and their analogues
for the protection against nitrogen mustard systemic toxicity.
2. MATERIALS AND METHODS
2.1 Chemicals Used
Nitrogen mustards [HN-1, bis-(2-chloroethyl)ethylamine;
HN-2,  mechlorethamine,  bis-(2-chloroethyl)methylamine;
HN-3, tris-(2-chloroethyl)amine]  and sulphur mustard (2,2-
dichloroethyl sulphide) were synthesised in the DRDE and
was found to be more than 99 per cent pure by gas
chromatographic analysis. Amifostine, DRDE-07 and their
analogues were also synthesised in DRDE and were found
to be 99 per cent pure by thin layer chromatography. N-
acetyl cysteine (NAC) and melatonin were purchased from
M/s Sigma Chemical Company (USA). Sodium thiosulphate
and other chemicals of high purity were from M/s Qualigens
(India) and M/s E-Merck (India).
2.2 Animals Treated
Randomly bred Swiss female mice (25-30 g) from
the institute’s animal facility were used for the study. The
animals were kept in polypropylene cages with sterilised
and dry paddy husk as a bedding material. Free access
to food and water was allowed until two hours before the
experiment. The care and maintenance of the animals were
taken as per the approved guidelines of the Committee for
the Purpose of Control and Supervision of Experiments on
Animals (CPCSEA), India. A day before percutaneous
administration of the mustard agents, hair on the back of
the animals were closely clipped using a pair of scissors.
Food and water were allowed two hours after the experiment.
All animal procedures were approved by the institutional
Animal Ethical Committee.
2.3 LD
50
 Determination
The analogues of DRDE-07, amifostine, N-acetyl cysteine,
and sodium thiosulphate were dissolved in distilled water,
and melatonin was dissolved in DMSO. The LD
50
 was determined
through oral, and intraperitoneal routes. LD
50
 of nitrogen
mustards (diluted in DMSO) and sulphur mustard (diluted
in PEG-300) were determined by exposing the animals to
increasing doses of mustard agents through percutaneous
route of administration. The diluted solution was smeared
uniformly on the back of the animals on a circular area of
1.5 cm diameter, using a gas-tight syringe (Harvard Apparatus,
USA). The body weight was recorded daily and the animals
were observed for mortality for 14 days. LD
50
 was determined
as per the moving average method [19].
2.4 Protective Efficacy of Analogues
Amifostine, DRDE-07, and their analogues and other
antidotes were administered orally 30 min prior to mustard
agent administration by percutaneous route. For amifostine,
N-acetyl cysteine, melatonin and sodium thiosulphate,
185 mg/kg, 250 mg/kg, 250 mg/kg, and 1000 mg/kg,
respectively was used.  For DRDE-07, 249 mg/kg, and
for other analogues, equimolar dose of DRDE-07 was
used [20]. Animals in the toxicant only groups received
distilled water as a pretreatment and then exposed to
mustard agents whereas PEG/DMSO was applied on the
back of animals in the control group. Body weight of
animals was recorded for 14 days and animals were monitored
for mortality and general health. LD
50
 of mustard agents
after pretreatment were then calculated by exposing the
animals to increasing doses of mustard agents. Protective
index (PI) was determined as a ratio of LD
50
 of mustard
agent after pretreatment to LD
50
 of mustard agent without
pretreatment. Another experiment was also performed in
which the antidotes were administered intraperitoneally,
30 min prior to mustard agents (HN-1, HN-2, HN-3 and
sulphur mustard) administration and PI was determined.
For intraperitoneal route, half of the oral dose of the
antidotes was given.
3. RESULTS
Table 1 shows the LD
50
 values of the various analogues
following oral and intraperitoneal routes in mice.  All deaths
occurred within 1h to 6 h and no delayed death was observed.
The animals appeared normal after 24 h.  Table 2, summarises
the prophylactic efficacy of various antidotes against
percutaneously administered HN-1, HN-2, HN-3 and sulphur
mustard. Compounds that showed marginal protection against
HN-1 were DRDE-10 and melatonin with a PI of 1.4. Compounds
that showed marginal protection against HN-2 were amifostine,
DRDE-07, DRDE-09, DRDE-30, DRDE-35, and melatonin
with a PI of 1.4. Compounds that showed marginal protection
against HN-3 were amifostine, DRDE-30, DRDE-35, sodium
thiosulphate and melatonin with a PI of 1.7. In case of
sulphur mustard, DRDE-07, DRDE-10, DRDE-21, DRDE-30,
and DRDE-35 gave a good protection with a PI of more
than 5.0. Amifostine and sodium thiosulphate gave a protection
of 4.5 and 4.0, respectively, while DRDE-09, N-acetyl cysteine
and melatonin gave less protection against sulphur mustard.
Table 3, summarises the prophylactic efficacy of
intraperitoneally administered antidotes against percutaneously
administered HN-2 and sulphur mustard. Intraperitoneally
administered amifostine, DRDE-30, sodium thiosulphate
and melatonin gave marginal protection against HN-2 with
a PI of 1.2. Intraperitoneally administered amifostine, DRDE-
07, DRDE-09, DRDE-10, DRDE-30, DRDE-35 and melatonin
gave excellent protection against percutaneously administered
sulphur mustard with a PI of more than 5.0.
4. DISCUSSION
Based on the LD
50
 determination, all the antidotes
showed more toxicity by the intraperitoneal route, except
sodium thiosulphate.  Amifostine and DRDE-07 are already
reported as antidotes against the toxic effect of suphur
mustard [10,18,21,22]. In this study also a similar result
was observed that DRDE-07 is better than amifostine against
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* All compounds were administered as 30 min pretreatment. Values are mg/kg. Figures in parentheses are
fiducial limits.
SM = sulphur mustard, Protection Index (PI) = LD
50
 with treatment/LD
50
 without treatment
Table 3. Protective effect of various antidotes (intraperitoneal administration) against
percutaneously administered HN-2 and sulphur mustard in mice.
Table 1. LD
50
 values of amifostine, DRDE-07 and their analogues and other antidotes in female mice
by oral and intraperitoneal routes of administration
Chemicals/  Oral LD50  Fiducial limits  I.P. LD50  Fiducial limits 
Drugs   (mg/kg)  (mg/kg)   (mg/kg)  (mg/kg) 
 
DRDE - 07  1247     793 - 1962  283  200 - 400 
DRDE - 09  1131  800 - 1600  283  200 - 400 
DRDE - 10  1902  1245 - 2907  283  200 - 400 
DRDE - 21  1131  597 - 2146  283  200 - 400 
DRDE - 30  4524  3200 - 6400  673  455 - 996 
DRDE - 35  2262  1600 - 3200  336  228 - 498 
Amifostine  1049  709 - 1552  951  622-1453 
N-acetyl cysteine  > 5000  -   336  228 - 498 
Melatonin  1345  909 - 1991  566  400 - 800 
Sodium thiosulphate > 5000  -   > 5000  - 
Table 2. Protective effect of various antidotes (oral administration) against percutaneously administered
HN-1, HN-2, HN-3 and sulphur mustard in mice
Chemicals/ Oral LD50 of PI LD50 of PI LD50 of PI LD50 of PI 
Drugs Dose* HN-1  HN-2   HN-3  SM 
 
Agent only     - 11.9 - 20.0 - 7.1 - 7.1 - 
  (7.8-18.2)  (12.7-31.5)  (3.2-15.7)  (5.0-10.0) 
+ DRDE-07 249 14.2  1.2 28.3 1.4 10.0 1.4 80.6 11.4 
  (10.0-20.0)  (20.0-40.0)  (6.1-16.3)  (50.0-125.8) 
+ DRDE-09 273 14.2 1.2 28.3  1.4 7.1 1.0 20.0 2.8 
  (10.0-20.0)  (20.0-40.0)  (5.0-10.0)  (12.3-32.6) 
+ DRDE-10 261 16.8 1.4 23.3 1.2 11.2 1.6 56.6 8.0 
  (11.4-24.9)  (16.1-35.2)  (6.2-20.4)  (29.8-107.3) 
+ DRDE-21 254 14.2  1.2 20.0 1.0 10.0 1.4 50.4 7.1 
  (10.0-20.0)  (12.7-31.5)  (6.1-16.3)  (22.6-114.1) 
+ DRDE-30 219 14.2  1.2 28.3 1.4 11.9 1.7 44.9 6.4 
  (10.0-20.0)  (20.0-40.0)  (7.8-18.2)  (21.1-95.4) 
+ DRDE-35 230 14.2 1.2 28.3 1.4 11.9 1.7 50.4 7.1 
  (6.4-31.5)  (20.0-40.0)  (7.8-18.2)  (22.3-114.1) 
+ Amifostine 185 14.2 1.2 28.3 1.4 11.9 1.7 31.8 4.5 
  (10.0-20.0)  (16.3-49.3)  (7.8-18.2)  (12.6-79.8) 
+ N-acetyl cysteine 250 14.2  1.2 20.0  1.0 10.0 1.4 16.8 2.4 
  (6.4-31.5)  (12.7-31.5)  (6.1-16.3)  (11.0-25.7) 
+ Melatonin 250 16.8 1.4 28.3 1.4 11.9 1.7 20.0 2.8 
  (11.4-24.9)  (20.0-40.0)  (7.8-18.2)  (12.3-32.6) 
+ Sodium   1000 14.2  1.2 23.8 1.2 11.9 1.7 28.3 4.0 
   thiosulphate  (6.4-31.5)  (16.8-35.2)  (7.8-18.2)  (16.3-49.3) 
 
Chemicals/ Oral LD
50
 of PI LD
50
 of PI
Drugs Dose* HN-2 S M
Agent only - 20.0 - 7.1 -
(12.7-32.6) (5.0-10.0)
+ DRDE-07 125 16.8 0.8 63.5 8.9
(11.0-25.7) (28.1-143.8)
+ DRDE-09 137 20.0 1.0 63.5 8.9
(12.7-32.6) (28.1-143.8)
+ DRDE-10 131 16.8 0.8 89.8 12.6
(11.0-25.7) (42.3-190.1)
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sulphur mustard toxicity [18]. It was also found that other
analogues of DRDE-07 are effective and give good protection,
but better one is DRDE-07 against sulphur mustard toxicity.
Since the action of nitrogen mustards and sulphur mustard
is expected to be similar, amifostine, DRDE-07, and related
compounds are a logical choice to test against nitrogen
mustards toxicity.
DRDE-07 and its analogues have been found to be
the most effective compounds for sulphur mustard systemic
toxicity. However, none of the compounds was found as
promising antidote for nitrogen mustard toxicity. But, these
compounds showed slightly more protection than already
recommended drugs like amifostine, N-acetyl cysteine, sodium
thiosulphate, and melatonin against percutaneously
administered nitrogen mustards. This indicates that nitrogen
mustards toxicity pattern is somewhat different from sulphur
mustard. However, DRDE-30 and DRDE-35 were over all
better and gave marginal protection against HN-2 and HN-
3. Probably these compounds may be beneficial in correcting
the biochemical changes induced by sublethal doses of
sulphur mustard as well as nitrogen mustards.[20] These
two compounds also have better safety in terms of LD
50
by oral and intraperitoneal routes.
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